Incyte's Jakafi gains priority review in polycythemia vera
This article was originally published in Scrip
Executive Summary
Granting a priority review, the FDA is expected to make a decision by 5 December whether it will expand the use of Incyte's oral JAK1/JAK2 inhibitor Jakafi (ruxolitinib) in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.